-
Mashup Score: 0Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML) - PubMed - 2 year(s) ago
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML) - 2 year(s) ago
Leukemia – Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#TP53 allelic status and CN-LOH in #CMML -Infrequent but relevant. Isochromosome 17q with monocytosis associated with poor outcomes @MarkGurneyOne @MayoCancerCare @md_padron @MoffittNews @LashoTerra https://t.co/BWoO94lIoh
-
-
Mashup Score: 2Are Hypomethylating Agents the Best First-Line Choice for Treating CMML? | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Ioannis Kotsianidis, MD Mrinal M. Patnaik, MBBS The U.S. Food and Drug Administration has approved two hypomethylating agents (HMAs), azacitidine and decitabine, for the treatment of chronic myelomonocytic leukemia (CMML), a rare and aggressive myeloid malignancy with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).1,2 Despite being widely…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Are Hypomethylating Agents the Best First-Line Choice for Treating CMML? https://t.co/qYm8gAjNY8 #CMML #DNMTi #TET2 @ASH_hematology
-
-
Mashup Score: 11
Section snippetsCRediT authorship contribution statementA.M compiled the clinical and genomics data, performed data analysis, and wrote the first draft of the manuscript. D.S, R.K, K.R, R.K, and E.P contributed patients and data. T.L and C.F performed and reviewed NGS data. M.P conceptualized the study and approved the final draft. All authors contributed to the writing of manuscript.Declaration…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Validation of Molecular International Prognostic Scoring System IPSS-M for #MDSMPNNOS @a_mangaonkar @md_padron @Ramikomrokji @MayoCancerCare @MoffittNews .. https://t.co/0ysNc9KTbM
-
-
Mashup Score: 0Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation - Nature Medicine - 2 year(s) ago
In a study of two children with the metabolic condition D-2-hydroxyglutaric aciduria type II, the drug enasidenib, developed as a selective mutant IDH2 inhibitor for treatment of acute myeloid leukemia, had beneficial effects on cardiac and neurodevelopmental abnormalities, indicating the potential for the repurposing of this drug for this hereditary condition.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation | Nature Medicine https://t.co/ldAAbPps4r
-
-
Mashup Score: 6Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome - PubMed - 2 year(s) ago
In this study, the utilization of a clinically applicable targeted-screening approach to test bone marrow specimens (with vacuolization) for the presence of previously undiagnosed VEXAS syndrome resulted in a positive detection rate of 87.5%.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS- PubMed @MdWarrington @HoratiuOlteanu @MayoCancerCare @MayoClinicCIM @VEXASfoundation https://t.co/kWyHDwPcjs
-
-
Mashup Score: 2Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings - PubMed - 2 year(s) ago
Cutaneous involvement is a common feature of VEXAS syndrome, and histopathologic findings exist on a spectrum of neutrophilic inflammatory dermatoses.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings. https://t.co/BEucVYB0Y9 #VEXAS @MayoCancerCare @MdWarrington
-
-
Mashup Score: 3Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML - PubMed - 2 year(s) ago
Inhibition of PIM kinases is a potential novel strategy for overcoming BETi persistence in myeloid neoplasms. Our data supports further clinical investigation of this combination.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML - PubMed Fantastic work by Chris Letson @md_padron @MoffittNews #CMML #BETi @MoritzBinderMD @MFZlab @MayoCancerCare https://t.co/1oiPZY5dMh
-
-
Mashup Score: 2Ageing-associated changes in transcriptional elongation influence longevity - Nature - 2 year(s) ago
Increases in transcriptional elongation speed with age affect organismal lifespan and ageing-related changes could be reversed with lifespan-extending interventions.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @AlbertVilella: Ageing-associated changes in transcriptional elongation influence longevity Cédric Debès et al. https://t.co/ODx5bPrCG5
-
-
Mashup Score: 2Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis - PubMed - 2 year(s) ago
Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis. https://t.co/IyNh0O9IPy | TET2 and classical monocytosis- spectrum across #CCUS and #CMML @LashoTerra @MayoCancerCare
-
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMM… https://t.co/JY4T5M5HfO Here is the link the paper! @MarkGurneyOne @AlkaliDr @md_padron